



# Restoring life after organ failure.

eGenesis is a biotechnology company committed to using its multiplex gene editing and genome engineering platform to revolutionize the treatment of organ failure. We have built a porcine genome engineering platform using advanced gene editing to create donors compatible for human transplantation. Our approach focuses on three classes of genetic edits to address retroviral risk and improve immunologic as well as molecular compatibility with human recipients.

18M

People globally suffer from organ failure

THE VAST MAJORITY WILL DIE WAITING FOR A TRANSPLANT

800K

Americans suffer from kidney failure

330K

Americans with acute liver decompensation

300K

Americans suffer from end-stage heart failure

\$80B+

Annual U.S. healthcare spend across end-stage organ disease

## Transformational Progress Since Inception

2017 —————> 2025

- First successful production of donors with retroviral inactivation (Science, 2017)
- Produced first transgenic donor carrying 3 classes of edits addressing historical challenges in cross-species transplantation (2021)
- Published landmark preclinical study (Nature, 2023) showing most extensive xenotransplant data and durable recipient survival
- Supplied EGEN-2784 kidney for world's first pig to living human kidney transplant (March 2024)
- Achieved record of 271 days dialysis independence for second patient to receive EGEN-2784 kidney (2025)

## Upcoming Portfolio Milestones

2026 —————> Next 18 Months —————>

- KIDNEY** **EGEN-2784** **Clinical**  
Initiation of 33-patient Phase 1/2/3 study of patients with kidney failure waitlisted for transplant. Demonstration of early clinical proof of concept (6 months dialysis independence)
- LIVER** **EGEN-5784 ELC** **Clinical**  
Completion of 20-patient Phase 1 study and demonstration of clinical proof of concept in ACLF patients.
- HEART** **EGEN-4467** **Preclinical**  
Completion of additional nonclinical studies to support IND filing and clarification of regulatory pathway for initial indication.

ORIGIN	Harvard University, 2016
DEVELOPMENT STAGE	Clinical
HEADQUARTERS	Cambridge, MA
CAPITAL RAISED	\$463M
LAST FINANCING	\$200M, 3 Q24

## Partnership Opportunities

- Pursuing regional and geographically focused partnerships
- Partnering with Immunology & Inflammation innovators, particularly in the areas of B- and T-cell suppression and complement inhibition

## Team

Experienced team of scientific, technical, and operational leaders with commitment to revolutionizing the treatment of organ failure

- Mike Curtis, Ph.D.    PRESIDENT & CHIEF EXECUTIVE OFFICER
- Jennifer Bergheiser    CHIEF BUSINESS OFFICER
- Jay Barth, M.D.    CHIEF MEDICAL OFFICER
- Susan Low, Ph.D.    HEAD OF DEVELOPMENT
- Wenning Qin, Ph.D.    SVP, INNOVATION
- Elizabeth Roberts    CHIEF PEOPLE OFFICER

Learn more [egenesisbio.com](https://egenesisbio.com)

Get in touch [investors@egenesisbio.com](mailto:investors@egenesisbio.com)